O	0	4	Dose	Dose	NN	B-NP
O	4	5	-	-	HYPH	O
O	6	9	and	and	CC	O
O	10	14	time	time	NN	B-NP
O	14	15	-	-	HYPH	B-NP
O	15	24	dependent	dependent	JJ	I-NP
O	25	32	effects	effect	NNS	I-NP
O	33	35	of	of	IN	B-PP
O	36	47	doxorubicin	doxorubicin	NN	B-NP
O	48	50	on	on	IN	B-PP
O	51	63	cytotoxicity	cytotoxicity	NN	B-NP
O	63	64	,	,	,	O
B-Cell	65	69	cell	cell	NN	B-NP
O	70	75	cycle	cycle	NN	I-NP
O	76	79	and	and	CC	O
O	80	89	apoptotic	apoptotic	JJ	B-NP
B-Cell	90	94	cell	cell	NN	I-NP
O	95	100	death	death	NN	I-NP
O	101	103	in	in	IN	B-PP
O	104	109	human	human	JJ	B-NP
B-Cell	110	115	colon	colon	NN	I-NP
I-Cell	116	122	cancer	cancer	NN	I-NP
I-Cell	123	128	cells	cell	NNS	I-NP
O	128	129	.	.	.	O

O	131	134	The	The	DT	B-NP
O	135	145	cytostatic	cytostatic	JJ	I-NP
O	146	150	drug	drug	NN	I-NP
O	151	162	doxorubicin	doxorubicin	NN	I-NP
O	163	165	is	be	VBZ	B-VP
O	166	167	a	a	DT	B-NP
O	168	172	well	well	RB	I-NP
O	172	173	-	-	HYPH	I-NP
O	173	178	known	know	VBN	I-NP
O	179	195	chemotherapeutic	chemotherapeutic	JJ	I-NP
O	196	201	agent	agent	NN	I-NP
O	202	207	which	which	WDT	B-NP
O	208	210	is	be	VBZ	B-VP
O	211	215	used	use	VBN	I-VP
O	216	218	in	in	IN	B-PP
O	219	228	treatment	treatment	NN	B-NP
O	229	231	of	of	IN	B-PP
O	232	233	a	a	DT	B-NP
O	234	238	wide	wide	JJ	I-NP
O	239	246	variety	variety	NN	I-NP
O	247	249	of	of	IN	B-PP
B-Cancer	250	257	cancers	cancer	NNS	B-NP
O	257	258	.	.	.	O

O	259	260	A	A	DT	B-NP
O	261	264	key	key	JJ	I-NP
O	265	271	factor	factor	NN	I-NP
O	272	274	in	in	IN	B-PP
O	275	278	the	the	DT	B-NP
O	279	287	response	response	NN	I-NP
O	288	290	of	of	IN	B-PP
B-Cell	291	297	cancer	cancer	NN	B-NP
I-Cell	298	303	cells	cell	NNS	I-NP
O	304	306	to	to	TO	B-PP
O	307	323	chemotherapeutic	chemotherapeutic	JJ	B-NP
O	324	329	drugs	drug	NNS	I-NP
O	330	332	is	be	VBZ	B-VP
O	333	336	the	the	DT	B-NP
O	337	347	activation	activation	NN	I-NP
O	348	350	of	of	IN	B-PP
O	351	354	the	the	DT	B-NP
O	355	364	apoptotic	apoptotic	JJ	I-NP
O	365	372	pathway	pathway	NN	I-NP
O	372	373	,	,	,	O
O	374	375	a	a	DT	B-NP
O	376	383	pathway	pathway	NN	I-NP
O	384	388	that	that	WDT	B-NP
O	389	391	is	be	VBZ	B-VP
O	392	397	often	often	RB	B-ADVP
O	398	406	impaired	impaired	JJ	B-ADJP
O	407	409	in	in	IN	B-PP
O	410	424	chemoresistant	chemoresistant	JJ	B-NP
B-Cell	425	430	colon	colon	NN	I-NP
I-Cell	431	437	cancer	cancer	NN	I-NP
I-Cell	438	443	cells	cell	NNS	I-NP
O	443	444	.	.	.	O

O	445	448	The	The	DT	B-NP
O	449	452	aim	aim	NN	I-NP
O	453	455	of	of	IN	B-PP
O	456	459	the	the	DT	B-NP
O	460	467	present	present	JJ	I-NP
O	468	473	study	study	NN	I-NP
O	474	477	was	be	VBD	B-VP
O	478	480	to	to	TO	B-VP
O	481	492	investigate	investigate	VB	I-VP
O	493	496	the	the	DT	B-NP
O	497	504	effects	effect	NNS	I-NP
O	505	507	of	of	IN	B-PP
O	508	519	doxorubicin	doxorubicin	NN	B-NP
O	520	522	in	in	IN	B-PP
B-Cell	523	526	Hct	Hct	NN	B-NP
I-Cell	526	527	-	-	HYPH	B-NP
I-Cell	527	530	116	116	CD	I-NP
I-Cell	531	536	human	human	JJ	I-NP
I-Cell	537	542	colon	colon	NN	I-NP
I-Cell	543	552	carcinoma	carcinoma	NN	I-NP
I-Cell	553	558	cells	cell	NNS	I-NP
O	559	561	in	in	IN	B-SBAR
O	562	567	order	order	NN	O
O	568	570	to	to	TO	B-VP
O	571	578	clarify	clarify	VB	I-VP
O	579	581	if	if	IN	B-SBAR
O	582	583	a	a	DT	B-NP
O	584	588	time	time	NN	I-NP
O	588	589	/	/	SYM	B-NP
O	589	602	concentration	concentration	NN	I-NP
O	603	608	range	range	NN	I-NP
O	609	612	for	for	IN	B-PP
O	613	620	optimal	optimal	JJ	B-NP
O	621	632	doxorubicin	doxorubicin	NN	I-NP
O	632	633	-	-	HYPH	B-NP
O	633	640	induced	induce	VBN	I-NP
O	641	650	apoptosis	apoptosis	NN	I-NP
O	651	657	exists	exist	VBZ	B-VP
O	657	658	.	.	.	O

O	659	661	We	We	PRP	B-NP
O	662	670	compared	compare	VBD	B-VP
O	671	672	a	a	DT	B-NP
O	673	682	treatment	treatment	NN	I-NP
O	683	691	schedule	schedule	NN	I-NP
O	692	696	were	be	VBD	B-VP
B-Cell	697	702	cells	cell	NNS	B-NP
O	703	707	were	be	VBD	B-VP
O	708	713	bolus	bolus	NN	B-NP
O	714	723	incubated	incubate	VBN	B-VP
O	724	727	for	for	IN	B-PP
O	728	730	3h	3h	NN	B-NP
O	731	735	with	with	IN	B-PP
O	736	747	doxorubicin	doxorubicin	NN	B-NP
O	748	756	followed	follow	VBN	B-VP
O	757	759	by	by	IN	B-PP
O	760	763	24h	24h	NN	B-NP
O	764	766	in	in	IN	B-PP
O	767	771	drug	drug	NN	B-NP
O	771	772	-	-	HYPH	B-NP
O	772	776	free	free	JJ	I-NP
O	777	783	medium	medium	NN	I-NP
O	783	784	,	,	,	O
O	785	789	with	with	IN	B-PP
O	790	791	a	a	DT	B-NP
O	792	802	continuous	continuous	JJ	I-NP
O	803	814	doxorubicin	doxorubicin	NN	I-NP
O	815	824	treatment	treatment	NN	I-NP
O	825	833	schedule	schedule	NN	I-NP
O	834	837	for	for	IN	B-PP
O	838	841	24h	24h	NN	B-NP
O	841	842	.	.	.	O

O	843	848	Bolus	Bolus	NN	B-NP
O	849	859	incubation	incubation	NN	I-NP
O	860	863	was	be	VBD	B-VP
O	864	871	carried	carry	VBN	I-VP
O	872	875	out	out	RP	B-PRT
O	876	878	to	to	TO	B-VP
O	879	888	determine	determine	VB	I-VP
O	889	896	effects	effect	NNS	B-NP
O	897	899	of	of	IN	B-PP
O	900	911	doxorubicin	doxorubicin	NN	B-NP
O	912	923	accumulated	accumulate	VBN	B-VP
O	924	930	during	during	IN	B-PP
O	931	934	the	the	DT	B-NP
O	935	940	first	first	JJ	I-NP
O	941	943	3h	3h	NN	I-NP
O	943	944	,	,	,	O
O	945	952	whereas	whereas	IN	O
O	953	963	continuous	continuous	JJ	B-NP
O	964	974	incubation	incubation	NN	I-NP
O	975	982	allowed	allow	VBD	B-VP
O	983	990	further	further	RBR	B-ADVP
O	991	992	(	(	(	O
O	992	1002	continuous	continuous	JJ	O
O	1002	1003	)	)	)	O
O	1004	1012	exposure	exposure	NN	B-NP
O	1013	1015	to	to	TO	B-PP
O	1016	1027	doxorubicin	doxorubicin	NN	B-NP
O	1027	1028	.	.	.	O

O	1029	1031	We	We	PRP	B-NP
O	1032	1037	found	find	VBD	B-VP
O	1038	1042	that	that	IN	B-SBAR
O	1043	1048	bolus	bolus	NN	B-NP
O	1049	1050	(	(	(	B-LST
O	1050	1052	3h	3h	LS	I-LST
O	1052	1053	)	)	)	O
O	1054	1063	treatment	treatment	NN	B-NP
O	1064	1068	with	with	IN	B-PP
O	1069	1080	doxorubicin	doxorubicin	NN	B-NP
O	1081	1089	resulted	result	VBD	B-VP
O	1090	1092	in	in	IN	B-PP
O	1093	1094	a	a	DT	B-NP
O	1095	1099	dose	dose	NN	I-NP
O	1099	1100	-	-	HYPH	B-NP
O	1100	1109	dependent	dependent	JJ	I-NP
O	1110	1118	decrease	decrease	NN	I-NP
O	1119	1121	of	of	IN	B-PP
O	1122	1128	viable	viable	JJ	B-NP
B-Cell	1129	1134	cells	cell	NNS	I-NP
O	1135	1138	and	and	CC	O
O	1139	1150	concomitant	concomitant	JJ	B-NP
O	1151	1159	increase	increase	NN	I-NP
O	1160	1162	of	of	IN	B-PP
O	1163	1172	apoptosis	apoptosis	NN	B-NP
O	1172	1173	.	.	.	O

O	1174	1186	Additionally	Additionally	RB	B-ADVP
O	1186	1187	,	,	,	O
O	1188	1193	bolus	bolus	NN	B-NP
O	1194	1195	(	(	(	B-LST
O	1195	1197	3h	3h	LS	I-LST
O	1197	1198	)	)	)	O
O	1199	1210	doxorubicin	doxorubicin	NN	B-NP
O	1211	1221	incubation	incubation	NN	I-NP
O	1222	1225	led	lead	VBD	B-VP
O	1226	1228	to	to	TO	B-PP
O	1229	1244	phosphorylation	phosphorylation	NN	B-NP
O	1245	1247	of	of	IN	B-PP
O	1248	1251	p53	p53	NN	B-NP
O	1252	1254	at	at	IN	B-PP
O	1255	1261	serine	serine	NN	B-NP
O	1262	1265	392	392	CD	I-NP
O	1265	1266	,	,	,	O
O	1267	1276	induction	induction	NN	B-NP
O	1277	1279	of	of	IN	B-PP
O	1280	1283	p21	p21	NN	B-NP
O	1283	1284	,	,	,	O
O	1285	1287	G2	G2	NN	B-NP
O	1288	1294	arrest	arrest	NN	I-NP
O	1295	1298	and	and	CC	I-NP
O	1299	1307	increase	increase	NN	I-NP
O	1308	1310	of	of	IN	B-PP
O	1311	1323	proapoptotic	proapoptotic	JJ	B-NP
O	1324	1331	protein	protein	NN	I-NP
O	1332	1335	Bax	Bax	NN	I-NP
O	1335	1336	.	.	.	O

O	1337	1339	In	In	IN	B-PP
O	1340	1348	contrast	contrast	NN	B-NP
O	1348	1349	,	,	,	O
O	1350	1360	continuous	continuous	JJ	O
O	1361	1362	(	(	(	O
O	1362	1365	24h	24h	JJ	B-ADJP
O	1365	1366	)	)	)	O
O	1367	1376	treatment	treatment	NN	B-NP
O	1377	1381	with	with	IN	B-PP
O	1382	1393	doxorubicin	doxorubicin	NN	B-NP
O	1394	1401	reduced	reduce	VBD	B-VP
O	1402	1405	the	the	DT	B-NP
O	1406	1412	number	number	NN	I-NP
O	1413	1415	of	of	IN	B-PP
O	1416	1422	living	live	VBG	B-VP
B-Cell	1423	1428	cells	cell	NNS	B-NP
O	1429	1433	with	with	IN	B-PP
O	1434	1436	no	no	DT	B-NP
O	1437	1445	parallel	parallel	JJ	I-NP
O	1446	1451	raise	raise	NN	I-NP
O	1452	1454	in	in	IN	B-PP
O	1455	1458	the	the	DT	B-NP
O	1459	1465	amount	amount	NN	I-NP
O	1466	1468	of	of	IN	B-PP
O	1469	1473	dead	dead	JJ	B-NP
B-Cell	1474	1479	cells	cell	NNS	I-NP
O	1479	1480	.	.	.	O

O	1481	1491	Continuous	Continuous	JJ	O
O	1492	1493	(	(	(	O
O	1493	1496	24h	24h	JJ	B-ADJP
O	1496	1497	)	)	)	O
O	1498	1507	treatment	treatment	NN	B-NP
O	1508	1512	with	with	IN	B-PP
O	1513	1514	5	5	CD	B-NP
O	1515	1521	microM	microM	NN	I-NP
O	1522	1533	doxorubicin	doxorubicin	NN	I-NP
O	1534	1542	resulted	result	VBD	B-VP
O	1543	1545	in	in	IN	B-PP
B-Cell	1546	1550	cell	cell	NN	B-NP
O	1551	1556	cycle	cycle	NN	I-NP
O	1557	1563	arrest	arrest	NN	I-NP
O	1564	1566	in	in	IN	B-PP
O	1567	1569	G0	G0	NN	B-NP
O	1569	1570	/	/	SYM	B-NP
O	1570	1572	G1	G1	NN	I-NP
O	1573	1578	phase	phase	NN	I-NP
O	1579	1583	that	that	WDT	B-NP
O	1584	1587	was	be	VBD	B-VP
O	1588	1595	neither	neither	DT	B-NP
O	1596	1607	accompanied	accompany	VBN	B-VP
O	1608	1610	by	by	IN	B-PP
O	1611	1626	phosphorylation	phosphorylation	NN	B-NP
O	1627	1630	and	and	CC	I-NP
O	1631	1641	activation	activation	NN	I-NP
O	1642	1644	of	of	IN	B-PP
O	1645	1648	p53	p53	NN	B-NP
O	1649	1652	nor	nor	CC	O
O	1653	1661	enhanced	enhance	VBN	B-VP
O	1662	1672	expression	expression	NN	B-NP
O	1673	1675	of	of	IN	B-PP
O	1676	1679	p21	p21	NN	B-NP
O	1679	1680	.	.	.	O

O	1681	1686	These	These	DT	B-NP
O	1687	1694	results	result	NNS	I-NP
O	1695	1702	suggest	suggest	VBP	B-VP
O	1703	1707	that	that	IN	B-SBAR
O	1708	1719	doxorubicin	doxorubicin	NN	B-NP
O	1720	1722	is	be	VBZ	B-VP
O	1723	1727	able	able	JJ	B-ADJP
O	1728	1730	to	to	TO	B-VP
O	1731	1737	induce	induce	VB	I-VP
B-Cell	1738	1742	cell	cell	NN	B-NP
O	1743	1748	death	death	NN	I-NP
O	1749	1751	by	by	IN	B-PP
O	1752	1761	apoptosis	apoptosis	NN	B-NP
O	1762	1766	only	only	RB	B-ADVP
O	1767	1769	at	at	IN	B-PP
O	1770	1780	particular	particular	JJ	B-NP
O	1781	1785	dose	dose	NN	I-NP
O	1786	1789	and	and	CC	I-NP
O	1790	1799	treatment	treatment	NN	I-NP
O	1800	1810	conditions	condition	NNS	I-NP
O	1811	1814	and	and	CC	O
O	1815	1820	imply	imply	VBP	B-VP
O	1821	1822	a	a	DT	B-NP
O	1823	1833	completely	completely	RB	I-NP
O	1834	1843	different	different	JJ	I-NP
B-Cell	1844	1852	cellular	cellular	JJ	I-NP
O	1853	1861	response	response	NN	I-NP
O	1862	1871	following	follow	VBG	B-PP
O	1872	1877	bolus	bolus	NN	B-NP
O	1878	1880	or	or	CC	O
O	1881	1891	continuous	continuous	JJ	B-NP
O	1892	1900	exposure	exposure	NN	I-NP
O	1901	1903	to	to	TO	B-PP
O	1904	1915	doxorubicin	doxorubicin	NN	B-NP
O	1915	1916	.	.	.	O

